retatrutide ly3437943 triple agonist gip glp-1 glucagon mechanism Beyond GLP -1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence Retatrutide (LY3437943) | Triple GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $7.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26

















:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)












